This case highlights the risk of vaccine-derived poliovirus causing paralytic poliomyelitis in immunodeficient individuals, emphasizing the need to switch from oral to inactivated polio vaccines to achieve global polio eradication.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to iVDPV risk in antibody-deficient children in Latin America; extends geographic evidence and leaves open eradication strategy refinements.
We describe a case of poliomyelitis in a 3-year-old Argentinean boy with X-linked hypogammaglobulinemia. The child had no history of polio vaccination, but a poliovirus isolated from a stool sample had 97.2% genetic similarity to the Sabin 1 vaccine strain. According to the WHO definition, this is the first case reported of a vaccine-derived poliovirus infection (iVDPV) recorded in continental Latin America. The use of live oral polio vaccine (OPV) in the polio eradication initiative has led to elimination of indigenous wild polio and certification of the Americas as polio-free in September 1994. 1 An important feature of polioviruses including the Sabin strains in OPV is their continued genetic variation through mutation and recombination. Selective pressures in the human intestine can cause partial reversion of the attenuated OPV strains to neurovirulence, resulting in vaccine-associated paralytic poliomyelitis (VAPP), 2 which is clinically identical with the paralysis caused by wild virus, affecting both vaccine recipients and their contacts. Risk of VAPP is highest after the first dose of OPV, estimated as 1 case per 750 000 children vaccinated, and 3000 times higher in immunocompromised persons. Only OPV causes VAPP, the only indigenous form of polio in those countries that have eradicated wild poliovirus. 3, 4 A major challenge for the polio eradication “endgame” strategy is the recent characterization of vaccine-derived polio viruses (VDPV), defined by the WHO as a Sabin vaccine virus that shows >1% drift in the VP1 region of the genome. 5 Both types of VDPV, those circulating in the population (cVDPV) and those from immunodeficient long term excretors (iVDPV), may acquire both the neurovirulence and the transmission characteristics of wild-type strains, leading to polio outbreaks. In this communication we present one case of paralytic polio caused by an iVDPV in a primary antibody-deficient child and the implications for the polio eradication endgame strategy. Case report. The patient is a boy born in 1995 from consanguineous parents living in the rural area of the city of San Pedro, in the province of Buenos Aires, a community with low socioeconomic status and poor hygiene conditions including lack of drinking water. The child had no history of medical problems, and his vaccination history consisted of only one dose of Calmette-Guérin bacillus at birth. He had not traveled out of his village and was not thought to have been in contact with persons recently vaccinated with OPV. At 3 years of age, in September 1998, he was hospitalized because of fever lasting for 24 h, associated with progressive asymmetric flaccid paralysis. Medical examination found Stage 1 malnutrition and decreased muscular tone in both legs and left arm, involving both proximal and distal muscles. Tendon reflexes were decreased in the right arm and absent in the left arm and both legs. No sensory loss was noted. Lumbar puncture revealed pleocytosis (82 cells/mm3) and elevated protein concentration (1.49 g/l). The glucose value was normal. He had a marked deficiency in immunoglobulins: 3.23 g/l for IgG (normal range, 8.2 to 13.2 g/l); 0.15 g/l for IgM (normal, 0.65 to 1.01 g/l); and 0.07 g/l for IgA (normal, 0.57 to 1.33 g/l). Salivary IgA was undetectable. T cell subsets were determined with flux cytometry. CD3 and CD8 populations were in the normal range, but in peripheral blood a small decrease was noted for the CD4 subset (29%; normal range, 36 to 46%) as well as for the CD19 subset (2%; normal range of 7 to 23%). X-linked hypogammaglobulinemia was diagnosed, and the child was given monthly therapy with iv gamma-globulin. Laboratory studies. Stool specimens obtained at the acute phase of the paralysis were inoculated into human rhabodomyosarcoma cells and transgenic mouse cell lines expressing the human poliovirus surface receptor (LB20), the WHO procedure for isolation and identification of polioviruses and also tested for enterovirus using a reverse transcription-nested PCR technique. Stool samples positive by viral isolation were investigated with the use of poliovirus-specific neutralizing antisera (CDC, Atlanta, GA) and with the Lim-Benyesh Melnick pool specific for polio and nonpolio enteroviruses and by PCR for pan-enterovirus and pan-polio Sabin 1, 2 and 3. The first stool sample yielded a poliovirus type 1, the major capsid protein (VP1) of which showed 97.2% genetic similarity to Sabin 1 vaccine strain, thus representing a VDPV by the WHO definition. All other stool samples were negative for poliovirus isolation. Three years later only nonpolio enteroviruses were isolated from four stool samples obtained 1 to 3 months apart during 1 year. At this time clinical assessment for residual neurologic deficit sequelae found hypotrophy of the left arm and both legs with skeletal deformities, without sensory loss. Electromyography confirmed the damage to the dorsal root ganglia. Discussion. The present case differs from “classical” cases of VAPP, because the magnitude of the genomic sequence changes observed in this case is characteristic of a VDPV. Such isolates were found in the Dominican Republic and Haiti 2000 to 2001 polio outbreak, 6 but to the best of our knowledge this is the first case reported in continental Latin America. Although the duration of poliovirus replication is limited in immunocompetent persons (from several days to 3 months), it may be considerably longer in immunodeficient persons. Patients with primary immunodeficiency disorders affecting the B cell system appear to be at highest risk for prolonged poliovirus replication and excretion. This group includes persons with X-linked or sporadic agammaglobulinemia and hypogammaglobulinemia, or common variable immunodeficiency, which is more frequent and often remains undiagnosed for many years. 2, 5, 7, 8 This case is 1 of 12 immunodeficient individuals thus far identified worldwide as long term poliovirus carriers by the WHO. 7 Shedding of Sabin type 1 and 2 neurovirulent revertant viruses has been reported up to 15 years. 7–9 To our knowledge our patient no longer excretes virus, possibly as result of to the therapeutic use of immunoglobulins. We cannot determine the time he was initially infected with the vaccine poliovirus, because stool specimens were obtained only after onset of paralysis. Knowing the rate of nucleotide substitutions in the poliovirus genome is relatively constant, 1% per year, 8 we can infer from the 2.8% difference from the Sabin vaccine strain that this poliovirus had replicated for 2 to 3 years before the onset of the paralytic disease. The most plausible explanation for the absence of other cases of paralytic polio in the community caused by this VDPV is the very high vaccination coverage rate (95 to 98%) with three doses of OPV in the first year of life in the area where the child lived. Low vaccination coverage and lack of supplementary immunization activities were believed to be the main risk factors in recent polio outbreaks due to circulating VDPV in Egypt, 10 Hispaniola, 6 the Philippines, 11 and Madagascar. 12 During widespread circulation of wild poliovirus strains, it made sense to interrupt that circulation rapidly by the application of OPV, VAPP cases being seen as the price to be paid to keep polio at bay. In 2002, public health circumstances are different: (1) the Western Pacific, European and Americas regions are certified polio-free; (2) the rapid progress of the global polio eradication initiative (a 99% decrease in cases during the last 12 years) has substantially decreased the risk of wild-type poliovirus importation; (3) in countries using OPV, even those polio-free, the WHO now recommends supplemental immunization campaigns 5 to avoid polio outbreaks resulting from prolonged circulation of VDPVs. As long as OPV is used, there is the potential for circulation of VDPVs. Eradication of all polio disease therefore ultimately requires the cessation of OPV use. 5 Because discontinuation of OPV will lead to a progressive decline in population immunity, infected persons without symptoms, which if similar to wild poliovirus would be estimated at 1 per 200 might shed VDPV in their stools, infecting an increasingly susceptible nonvaccinated population, 13 unless polio immunization is continued by inclusion of IPV in routine immunization schedules. Only the exclusive use of IPV will eliminate the shedding of VDPVs and totally eliminate any risk of VAPP, while ensuring individual and collective protection. The progressive switching of routine immunization with OPV to exclusive use of IPV until the total elimination of the risks of circulating polioviruses has already occurred in many countries like the US, Canada and most European countries. This should now be considered for Central and South American countries. Until this occurs OPV should not be given to immunodeficient individuals or household contacts of individuals who have immunodeficiency diseases or immunodepression (caused by disease or therapy) or if there is suspected familial immunodeficiency. In all these situations only IPV should be given. 14 Acknowledgments. We thank Dr. M. Bontempi, Dr. M. Rivas, Dr. L. Brizuela and Dr. E. Insua for their scientific contribution.
No takes yet. Share an insight, caveat, or question.
Hidalgo et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: